NCT00434317CompletedPhase 4
A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Novartis
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Measurement of pain assessed by a Visual Analogue Scale (VAS)
Study Overview
Brief Summary
This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
ZOL446
Experimental
Intervention: Zoledronic acid (Drug)
Outcomes
Primary Outcomes
Measurement of pain assessed by a Visual Analogue Scale (VAS)
Time Frame: throughout the study
Secondary Outcomes
- Quality of Life assessment at baseline and last visit(throughout the study)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Withdrawn
Phase 4
Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.Multiple MyelomaNCT00242528Novartis
Terminated
Phase 3
Maintaining Bone Strength in Men With Prostate CancerProstate CancerNCT00391950Novartis300
Terminated
Phase 3
Zoledronic Acid in MS-patients With OsteoporosisMultiple SclerosisOsteoporosisNCT01166178Novartis29
Completed
Phase 3
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation PeriodPaget's Disease of BoneNCT00051636Novartis Pharmaceuticals172
Completed
Phase 4
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer PatientsFirst or Second Line HER2-negative Breast CancerMetastatic Disease Without Bone MetastasisNCT01129336Novartis Pharmaceuticals44